Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; Newman Yeilding; Cynthia Guzzo; Ming-Chun Hsu; Yuhua Wang; Shu Li; Lisa T Dooley; Kristian Reich

doi:10.1016/s0140-6736(08)60726-6

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

The Lancet ◽

10.1016/s0140-6736(08)60726-6 ◽

2008 ◽

Vol 371 (9625) ◽

pp. 1675-1684 ◽

Cited By ~ 970

Author(s):

Kim A Papp ◽

Richard G Langley ◽

Mark Lebwohl ◽

Gerald G Krueger ◽

Philippe Szapary ◽

...

Keyword(s):

Monoclonal Antibody ◽

Controlled Trial ◽

Interleukin 12 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Get full-text (via PubEx)

Faculty Opinions recommendation of Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1108987.566149 ◽

2008 ◽

Author(s):

Johann Gudjonsson

Keyword(s):

Monoclonal Antibody ◽

Controlled Trial ◽

Interleukin 12 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Get full-text (via PubEx)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

The Lancet ◽

10.1016/s0140-6736(08)60725-4 ◽

2008 ◽

Vol 371 (9625) ◽

pp. 1665-1674 ◽

Cited By ~ 1084

Author(s):

Craig L Leonardi ◽

Alexa B Kimball ◽

Kim A Papp ◽

Newman Yeilding ◽

Cynthia Guzzo ◽

...

Keyword(s):

Monoclonal Antibody ◽

Controlled Trial ◽

Interleukin 12 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Get full-text (via PubEx)

Faculty Opinions recommendation of Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718205974.793488589 ◽

2013 ◽

Author(s):

Kamran Ghoreschi

Keyword(s):

Monoclonal Antibody ◽

Controlled Trial ◽

Interleukin 12 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Get full-text (via PubEx)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Yearbook of Dermatology and Dermatologic Surgery ◽

10.1016/s0093-3619(08)79142-1 ◽

2009 ◽

Vol 2009 ◽

pp. 145-146

Author(s):

B.H. Thiers

Keyword(s):

Monoclonal Antibody ◽

Controlled Trial ◽

Interleukin 12 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Get full-text (via PubEx)